Cystic Fibrosis: A Brief Review of Pathogenesis, Clinical Features, Diagnosis and Therapies

Uttam Garg; Christopher M. Oermann

doi:10.53941/ijctm.2025.1000025

Abstract

Cystic fibrosis (CF) is an autosomal recessive disorder caused by variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes CFTR protein, a chloride and bicarbonate channel essential for epithelial ion transport. CF occurs across all racial and ethnic groups, though incidence is highest among individuals of Northern European ancestry. Advances in newborn screening, diagnosis, and treatment have transformed CF from a fatal childhood disease into a chronic, manageable condition extending into adulthood. Over 2000 CFTR variants have been identified and classified into six groups based on their impact on protein production, processing, and function. Variants in Classes I–III generally result in more severe disease, while Classes IV–VI are associated with milder phenotypes. CF primarily affects the lungs, pancreas, gastrointestinal tract, hepatobiliary system, and reproductive system. Progressive pulmonary disease remains the leading cause of morbidity and mortality, driven by mucus obstruction, chronic infection, and neutrophil-mediated inflammation. Pancreatic insufficiency, malabsorption, CF-related diabetes, liver disease, and infertility are common systemic features. Modern management combines symptomatic therapies with CFTR modulators such as ivacaftor and triple-combination regimens which have revolutionized outcomes. Median survival now exceeds 50 years, with ongoing research targeting universal therapies and gene-based approaches.

References

1.
2023 Patient Registry Annual Data Report. Available online: https://www.cff.org/medical-professionals/patient-registry (accessed on 18 August 2025).
2.
Ong, T.; Ramsey, B.W. Cystic Fibrosis: A Review. JAMA 2023, 329, 1859–1871.
3.
Sheppard, D.N.; Welsh, M.J. Structure and function of the CFTR chloride channel. Physiol. Rev. 1999, 79, S23–S45.
4.
Grasemann, H.; Ratjen, F. Cystic Fibrosis. N. Engl. J. Med. 2023, 389, 1693–1707.
5.
Dickinson, K.M.; Collaco, J.M. Cystic Fibrosis. Pediatr. Rev. 2021, 42, 55–67.
6.
Savant, A.; Lyman, B.; Bojanowski, C.; et al. Cystic Fibrosis. In GeneReviews®; Adam, M.P., Feldman, J., Mirzaa, G.M.; et al., Eds.; University of Washington: Seattle, WA, USA, 2025.
7.
Kelly, T.; Buxbaum, J. Gastrointestinal Manifestations of Cystic Fibrosis. Dig. Dis. Sci. 2015, 60, 1903–1913.
8.
Flass, T.; Narkewicz, M.R. Cirrhosis and other liver disease in cystic fibrosis. J. Cyst. Fibros. 2013, 12, 116–124.
9.
van der Doef, H.P.; Kokke, F.T.; van der Ent, C.K.; et al. Intestinal obstruction syndromes in cystic fibrosis: Meconium ileus, distal intestinal obstruction syndrome, and constipation. Curr. Gastroenterol. Rep. 2011, 13, 265–270.
10.
McDonald, C.M.; Reid, E.K.; Pohl, J.F.; et al. Cystic fibrosis and fat malabsorption: Pathophysiology of the cystic fibrosis gastrointestinal tract and the impact of highly effective CFTR modulator therapy. Nutr. Clin. Pract. 2024, 39 (Suppl. 1), S57–S77.
11.
Iafusco, F.; Maione, G.; Rosanio, F.M.; et al. Cystic Fibrosis-Related Diabetes (CFRD): Overview of Associated Genetic Factors. Diagnostics 2021, 11, 572.
12.
Edenborough, F.P. Women with cystic fibrosis and their potential for reproduction. Thorax 2001, 56, 649–655.
13.
Hughan, K.S.; Daley, T.; Rayas, M.S.; et al. Female reproductive health in cystic fibrosis. J. Cyst. Fibros. 2019, 18 (Suppl. 2), S95–S104.
14.
Quittner, A.L.; Abbott, J.; Georgiopoulos, A.M.; et al. International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax 2016, 71, 26–34.
15.
CLSI. Sweat Testing: Sample Collection and Quantitative Chloride Analysis, Approved Guideline, 5th ed.; CLSI document C34-Ed5; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2024.
16.
Guo, J.; Garratt, A.; Hill, A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J. Cyst. Fibros. 2022, 21, 456–462.
17.
Bell, S.C.; Mall, M.A.; Gutierrez, H.; et al. The future of cystic fibrosis care: A global perspective. Lancet Respir. Med. 2020, 8, 65–124.
18.
Taylor-Cousar, J.L.; Robinson, P.D.; Shteinberg, M.; et al. CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis. Lancet 2023, 402, 1171–1184.
19.
Wilson, C. Future therapies for cystic fibrosis. Lancet Respir. Med. 2022, 10, e75–e76.
20.
Allen, L.; Allen, L.; Carr, S.B.; et al. Future therapies for cystic fibrosis. Nat. Commun. 2023, 14, 693.
21.
Mullard, A. FDA approves next-generation triple therapy for cystic fibrosis. Nat. Rev. Drug Discov. 2025, 24, 83.

Scilight Press

Author Information

Abstract

Keywords

References

About Scilight

Journals

Publishing Policies

Contact Us